logo
  

Lawsuit Filed Against Kimberly-Clark Over Ebola Protective Gowns

Southern California-based law firm Eagan Avenatti, LLP said Thursday that it has filed a class action lawsuit in the United States District Court for the Central District of California in Los Angeles, alleging that Kimberly-Clark Corp. (KMB) has committed fraud in the marketing and selling of certain of their protective medical gowns.

In particular, the suit states that Kimberly-Clark has falsely represented to the FDA, health care workers and the general public that the company's "MICROCOOL Breathable High Performance Surgical Gowns" are impermeable and provide protection against Ebola despite the fact that the company has known since 2013 that those gowns failed industry tests and do not meet relevant standards, thus placing healthcare professionals and patients at considerable risk for infection and serious bodily harm.

According to the complaint, Kimberly-Clark has knowingly misled the medical community, regulators and the general public about the safety of the surgical gowns and even after learning of multiple test failures, failed to alert the FDA, healthcare professionals and patients.

The lawsuit seeks damages in excess of $500 million and is brought on behalf of lead plaintiff and well respected surgeon Hrayr Shahinian, together with about 500,000 others similarly situated.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT